-

Shareholder Alert: Robbins LLP Reminds Investors Merit Medical Systems, Inc. (MMSI) Sued for Misleading Shareholders

SAN DIEGO & SOUTH JORDAN, Utah--(BUSINESS WIRE)--Shareholder rights law firm Robbins LLP reminds investors that a purchaser of Merit Medical Systems, Inc. (NASDAQ: MMSI) filed a class action complaint for alleged violations of the Securities Exchange Act of 1934 between February 26, 2019 and October 30, 2019. Merit manufactures and markets disposable medical devices for interventional, diagnostic, and therapeutics.

If you suffered a loss as a result of Merit's misconduct, click here.

Merit Medical Systems, Inc. (MMSI) Accused of Misleading Shareholders

According to the complaint, in 2018, Merit acquired Becton, Dickinson and Company, Cianna Medical, Inc., and Vascular Insights, LLC for a total of $360 million. In February 2019, Merit touted fourth quarter 2018 and fiscal year 2018 results with revenue growth of 8-10% and forecasted net sales of $1.011 billion to $1.030 billion for fiscal year 2019 ("FY19"). Merit also assured it was successfully integrating its acquired companies, its product pipeline was full, and expenses were being kept under tight control. In April 2019, Merit reported first quarter 2019 results that had "met and exceeded [its] expectations" and reaffirmed its FY19 guidance. However, in July 2019, Merit's second quarter 2019 financial results fell short of analyst expectations and the Company cut its FY19 sales outlook to $1.007-1.029 billion, citing "slower than expected uptake of acquired products" that were "short term" issues. Then, on October 30, 2019, Merit reported third quarter 2019 results, slashing its FY19 revenue guidance by 20% and reporting significant operational issues in all aspects of its business, many of which were due to defendants' "own overestimation and forecasting." Following these disclosures, Merit's stock declined a staggering 62% to close at $20.66 per share.

Merit Medical Systems, Inc. (MMSI) Shareholders Have Legal Options

Contact us to learn more:
Leo Kandinov
(800) 350-6003
lkandinov@robbinsllp.com
Shareholder Information Form

Robbins LLP is a nationally recognized leader in shareholder rights law. The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits, and has helped its clients realize more than $1 billion of value for themselves and the companies in which they have invested. Click here to receive free alerts from Stock Watch when companies engage in wrongdoing.

Attorney Advertising. Past results do not guarantee a similar outcome.

Contacts

Leo Kandinov
Robbins LLP
5040 Shoreham Place
San Diego, CA 92122
lkandinov@robbinsllp.com
(619) 525-3990 or Toll Free (800) 350-6003
www.robbinsllp.com

Robbins LLP

NASDAQ:MMSI

Release Versions
$Cashtags

Contacts

Leo Kandinov
Robbins LLP
5040 Shoreham Place
San Diego, CA 92122
lkandinov@robbinsllp.com
(619) 525-3990 or Toll Free (800) 350-6003
www.robbinsllp.com

More News From Robbins LLP

Stockholder Alert: Robbins LLP Informs Investors of the Flotek Industries, Inc. (FTK) Class Action

SAN DIEGO--(BUSINESS WIRE)--Shareholder rights law firm Robbins LLP informs investors that a class action was filed on behalf of all persons and entities who purchased or otherwise acquired Flotek Industries, Inc. (NYSE: FTK) securities between August 3, 2026 and August 17, 2026 (the "Class Period"). Flotek is an energy technology and services company.The complaint alleges that Flotek misled investors by failing to disclose the cancellation of its $400m Puerto Rican deal.Investors who suffered s...

Robbins LLP Encourages WSE Stockholders with Large Losses to Seek Counsel for the Securities Class Action Lawsuit Against Wise Group plc

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP reminds investors that a securities class action has been filed on behalf of all persons and entities that purchased or otherwise acquired Wise Group plc (NASDAQ: WSE) securities between May 11, 2026 and July 23, 2026 (the "Class Period").The complaint alleges that Wise and certain of its senior executives violated the federal securities laws by making materially false and/or misleading statements regarding the Company's anti-money laundering compliance, a...

Robbins LLP Urges Investors of ARS Pharmaceuticals Inc. to Contact the Firm for Information About the SPRY Securities Class Action Lawsuit

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP reminds shareholders that a securities class action has been filed on behalf of all investors who purchased or otherwise acquired ARS Pharmaceuticals Inc. (NASDAQ: SPRY) securities between March 9, 2026 and June 24, 2026 (the "Class Period"). ARS is a clinical stage biopharmaceutical company focused on the development and commercialization of neffy for needle-free intranasal delivery of epinephrine for emergency treatment of Type 1 allergic reactions, incl...
Back to Newsroom